Glaukos Corp Aktie News

The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.

Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Divisi...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% ...

The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp , giving patients a less painful and more convenient option to treat a progressive condition that can severely affect vision, the company said on Monday.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). Epioxa is a groundbreaking advanc...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held Oct...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The company's management will discuss the results during a...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a ma...